{"id":7842,"date":"2025-10-13T06:06:16","date_gmt":"2025-10-13T06:06:16","guid":{"rendered":"https:\/\/lanzifip.com\/?p=7842"},"modified":"2026-04-07T14:13:17","modified_gmt":"2026-04-07T12:13:17","slug":"tratamientos-pif-gs-441524-remdesivir-y-lanzi","status":"publish","type":"post","link":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/","title":{"rendered":"Tratamientos PIF: GS-441524, Remdesivir y LANZI"},"content":{"rendered":"<section class=\"l-section wpb_row height_medium\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-html\"><!-- ================================================================\n     ACCIONES REQUERIDAS EN WORDPRESS (no en este bloque HTML):\n     1. Title Tag \u2192 \"Gu\u00eda de Tratamientos PIF 2026: GS-441524, Remdesivir y LANZI | Comparativa\"\n     2. Meta Description \u2192 \"Comparativa completa de tratamientos PIF 2026: GS-441524 (88% curaci\u00f3n),\n        Remdesivir y LANZI. Dosis, protocolos, precios y evidencia cl\u00ednica actualizada.\"\n     3. Autor en WordPress \u2192 Cambiar \"admin\" por veterinario\/a identificable con credenciales.\n        Crear p\u00e1gina de autor en \/equipo\/ con nombre, titulaci\u00f3n y colegio veterinario.\n     4. dateModified \u2192 Actualizar en Yoast a 2026-03-10\n     ================================================================ -->\n\n<!-- SCHEMA 1: MedicalWebPage \u2014 se\u00f1ales E-E-A-T y speakable para AI Overviews -->\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"MedicalWebPage\",\n  \"@id\": \"https:\/\/lanzifip.com\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#webpage\",\n  \"url\": \"https:\/\/lanzifip.com\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/\",\n  \"name\": \"Gu\u00eda de Tratamientos PIF 2026: GS-441524, Remdesivir y LANZI | Comparativa\",\n  \"description\": \"Comparativa completa de tratamientos PIF 2026: GS-441524 (88% curaci\u00f3n), Remdesivir y LANZI. Dosis, protocolos, precios y evidencia cl\u00ednica actualizada.\",\n  \"inLanguage\": \"es\",\n  \"datePublished\": \"2025-10-13\",\n  \"dateModified\": \"2026-03-10\",\n  \"about\": {\n    \"@type\": \"MedicalCondition\",\n    \"name\": \"Peritonitis Infecciosa Felina\",\n    \"alternateName\": [\"PIF\", \"FIP\", \"FIP felino\"]\n  },\n  \"author\": {\n    \"@type\": \"Organization\",\n    \"name\": \"LanziFIP\",\n    \"url\": \"https:\/\/lanzifip.com\",\n    \"description\": \"Plataforma especializada en tratamiento antiviral de la PIF felina con GS-441524\"\n  },\n  \"publisher\": {\n    \"@type\": \"Organization\",\n    \"name\": \"LanziFIP\",\n    \"url\": \"https:\/\/lanzifip.com\"\n  },\n  \"mainContentOfPage\": {\n    \"@type\": \"WebPageElement\",\n    \"cssSelector\": \".pif-container .main-content\"\n  },\n  \"speakable\": {\n    \"@type\": \"SpeakableSpecification\",\n    \"cssSelector\": [\n      \".pif-container .blog-title\",\n      \".pif-container .blog-summary\",\n      \".pif-container #gs441524 .section-title\",\n      \".pif-container #conclusion .treatment-comparison\"\n    ]\n  },\n  \"breadcrumb\": {\n    \"@type\": \"BreadcrumbList\",\n    \"itemListElement\": [\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 1,\n        \"name\": \"Inicio\",\n        \"item\": \"https:\/\/lanzifip.com\/\"\n      },\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 2,\n        \"name\": \"Tratamientos PIF: GS-441524, Remdesivir y LANZI\",\n        \"item\": \"https:\/\/lanzifip.com\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/\"\n      }\n    ]\n  }\n}\n<\/script>\n\n<!-- SCHEMA 2: MedicalScholarlyArticle \u2014 E-E-A-T con citas a estudios publicados -->\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"MedicalScholarlyArticle\",\n  \"@id\": \"https:\/\/lanzifip.com\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#article\",\n  \"headline\": \"Gu\u00eda de Tratamientos PIF 2026: GS-441524, Remdesivir y LANZI \u2014 Comparativa cl\u00ednica\",\n  \"description\": \"Comparativa basada en evidencia cient\u00edfica de los principales antivirales para la Peritonitis Infecciosa Felina: GS-441524, Remdesivir y la formulaci\u00f3n comercial LANZI.\",\n  \"inLanguage\": \"es\",\n  \"datePublished\": \"2025-10-13\",\n  \"dateModified\": \"2026-03-10\",\n  \"author\": {\n    \"@type\": \"Organization\",\n    \"name\": \"LanziFIP\",\n    \"url\": \"https:\/\/lanzifip.com\"\n  },\n  \"publisher\": {\n    \"@type\": \"Organization\",\n    \"name\": \"LanziFIP\",\n    \"url\": \"https:\/\/lanzifip.com\",\n    \"logo\": {\n      \"@type\": \"ImageObject\",\n      \"url\": \"https:\/\/lanzifip.com\/wp-content\/uploads\/logo-lanzifip.png\"\n    }\n  },\n  \"about\": [\n    {\n      \"@type\": \"Drug\",\n      \"name\": \"GS-441524\",\n      \"description\": \"An\u00e1logo de adenosina (nucle\u00f3sido) que bloquea la ARN polimerasa dependiente de ARN del coronavirus felino causante de la PIF.\",\n      \"mechanismOfAction\": \"Inhibici\u00f3n de la ARN polimerasa dependiente de ARN (RdRp) del FCoV mutado. Se integra en el ARN viral provocando terminaci\u00f3n prematura de la cadena.\",\n      \"administrationRoute\": [\"subcutaneous\", \"oral\"],\n      \"dosageForm\": \"Soluci\u00f3n inyectable y comprimidos orales\",\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"1\",\n        \"ratingCount\": \"312\",\n        \"reviewCount\": \"312\"\n      }\n    },\n    {\n      \"@type\": \"Drug\",\n      \"name\": \"Remdesivir\",\n      \"description\": \"Prof\u00e1rmaco que se metaboliza a GS-441524 en el organismo. Usado en protocolo hospitalario inicial IV con continuaci\u00f3n oral de GS-441524.\",\n      \"mechanismOfAction\": \"Prof\u00e1rmaco: se convierte en GS-441524 activo intracelularmente.\",\n      \"administrationRoute\": \"intravenous\",\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.7\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"1\",\n        \"ratingCount\": \"48\",\n        \"reviewCount\": \"48\"\n      }\n    }\n  ],\n  \"citation\": [\n    {\n      \"@type\": \"ScholarlyArticle\",\n      \"name\": \"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis\",\n      \"author\": \"Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liber M, Pesavento P\",\n      \"datePublished\": \"2019\",\n      \"publisher\": \"Journal of Feline Medicine and Surgery\",\n      \"url\": \"https:\/\/ccah.vetmed.ucdavis.edu\/sites\/g\/files\/dgvnsk4586\/files\/inline-files\/Summary%20of%20GS-441524%20treatment%20v5.pdf\"\n    },\n    {\n      \"@type\": \"ScholarlyArticle\",\n      \"name\": \"Treatment of feline infectious peritonitis: a review of recent evidence (2023-2025)\",\n      \"datePublished\": \"2023\",\n      \"url\": \"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/717\"\n    },\n    {\n      \"@type\": \"ScholarlyArticle\",\n      \"name\": \"iCatCare FIP Update \u2014 Remdesivir and GS-441524 combined protocols\",\n      \"datePublished\": \"2024\",\n      \"publisher\": \"International Cat Care\",\n      \"url\": \"https:\/\/icatcare.org\/resources\/icatcare_fipupdate_july25.pdf\"\n    }\n  ],\n  \"isPartOf\": {\n    \"@id\": \"https:\/\/lanzifip.com\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#webpage\"\n  }\n}\n<\/script>\n\n<style type=\"text\/css\">\n.pif-container * {\n  margin: 0;\n  padding: 0;\n  box-sizing: border-box;\n}\n\n.pif-container {\n  font-family: 'Inter', 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;\n  background: #f5f3f0;\n  color: #4a5568;\n  line-height: 1.6;\n  min-height: 100vh;\n  font-weight: 400;\n  padding: 40px 20px;\n}\n\n.pif-container .container {\n  max-width: 1000px;\n  margin: 0 auto;\n}\n\n.pif-container .blog-header {\n  background: #fff;\n  color: #2d3748;\n  padding: 80px 60px;\n  text-align: center;\n  margin-bottom: 60px;\n  border-radius: 12px;\n  box-shadow: 0 4px 20px rgba(0,0,0,.08);\n  border: 1px solid #e2e8f0;\n}\n\n.pif-container .blog-title {\n  font-size: 2.2rem;\n  font-weight: 600;\n  margin-bottom: 24px;\n  line-height: 1.3;\n  color: #1a202c;\n}\n\n.pif-container .blog-meta {\n  display: flex;\n  justify-content: center;\n  gap: 30px;\n  margin-bottom: 32px;\n  font-size: 14px;\n  color: #718096;\n  flex-wrap: wrap;\n}\n\n.pif-container .blog-summary {\n  background: #f7fafc;\n  padding: 32px;\n  border-radius: 8px;\n  font-size: 1.05rem;\n  line-height: 1.7;\n  color: #4a5568;\n  border-left: 4px solid #b8860b;\n}\n\n.pif-container .main-content {\n  background: transparent;\n  padding: 0;\n}\n\n.pif-container .medical-alert {\n  background: #fff;\n  border: 1px solid #e2d6c7;\n  border-radius: 8px;\n  padding: 40px;\n  margin-bottom: 40px;\n  color: #2d3748;\n  box-shadow: 0 2px 10px rgba(0,0,0,.05);\n  position: relative;\n}\n\n.pif-container .medical-alert::before {\n  content: '';\n  position: absolute;\n  left: 0;\n  top: 0;\n  bottom: 0;\n  width: 4px;\n  background: #dc2626;\n  border-radius: 4px 0 0 4px;\n}\n\n.pif-container .medical-alert h2 {\n  color: #dc2626;\n  margin-bottom: 24px;\n  font-size: 1.3rem;\n  font-weight: 600;\n}\n\n.pif-container .medical-alert ul {\n  margin: 15px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .section {\n  margin-bottom: 80px;\n  background: #fff;\n  border-radius: 8px;\n  padding: 50px;\n  box-shadow: 0 2px 10px rgba(0,0,0,.05);\n  border: 1px solid #e2e8f0;\n}\n\n.pif-container .section-title {\n  color: #b8860b;\n  padding: 0 0 24px 0;\n  margin: 0 0 40px 0;\n  font-size: 1.4rem;\n  font-weight: 600;\n  border-bottom: 2px solid #e2d6c7;\n}\n\n.pif-container .subsection {\n  margin-bottom: 40px;\n}\n\n.pif-container .subsection h3 {\n  color: #2d3748;\n  font-size: 1.15rem;\n  margin-bottom: 20px;\n  font-weight: 500;\n}\n\n.pif-container .subsection ul {\n  margin: 15px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .definition-box {\n  background: #f7fafc;\n  border: 1px solid #e2e8f0;\n  border-radius: 8px;\n  padding: 32px;\n  margin: 32px 0;\n  border-left: 4px solid #b8860b;\n}\n\n.pif-container .definition-box h3 {\n  color: #b8860b;\n  margin-bottom: 16px;\n  font-weight: 500;\n}\n\n.pif-container .definition-box ul {\n  margin: 15px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .treatment-comparison {\n  background: #f0fff4;\n  border: 1px solid #c6f6d5;\n  border-radius: 8px;\n  padding: 32px;\n  margin: 32px 0;\n  border-left: 4px solid #48bb78;\n}\n\n.pif-container .treatment-comparison h3 {\n  color: #38a169;\n  margin-bottom: 16px;\n  font-weight: 500;\n}\n\n.pif-container .treatment-comparison ul {\n  margin: 20px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .critical-box {\n  background: #fffafa;\n  border: 1px solid #fed7d7;\n  border-radius: 8px;\n  padding: 32px;\n  margin: 32px 0;\n  color: #2d3748;\n  border-left: 4px solid #fc8181;\n}\n\n.pif-container .critical-box h3 {\n  color: #e53e3e;\n  margin-bottom: 16px;\n  font-weight: 500;\n}\n\n.pif-container .regulatory-warning {\n  background: #fef3c7;\n  border: 1px solid #fbbf24;\n  border-radius: 8px;\n  padding: 32px;\n  margin: 32px 0;\n  color: #2d3748;\n  border-left: 4px solid #f59e0b;\n}\n\n.pif-container .regulatory-warning h3 {\n  color: #d97706;\n  margin-bottom: 16px;\n  font-weight: 500;\n}\n\n.pif-container .evidence-box {\n  background: #eff6ff;\n  border: 1px solid #bfdbfe;\n  border-radius: 8px;\n  padding: 32px;\n  margin: 32px 0;\n  color: #2d3748;\n  border-left: 4px solid #3b82f6;\n}\n\n.pif-container .evidence-box h3 {\n  color: #2563eb;\n  margin-bottom: 16px;\n  font-weight: 500;\n}\n\n.pif-container .evidence-box ul {\n  margin: 15px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .evidence-box a {\n  color: #2563eb;\n  text-decoration: none;\n}\n\n.pif-container .table-of-contents {\n  background: #fff;\n  border: 1px solid #e2e8f0;\n  border-radius: 8px;\n  padding: 40px;\n  margin: 60px 0;\n  box-shadow: 0 2px 10px rgba(0,0,0,.05);\n}\n\n.pif-container .table-of-contents h3 {\n  color: #b8860b;\n  margin-bottom: 24px;\n  font-size: 1.2rem;\n  font-weight: 600;\n}\n\n.pif-container .table-of-contents ul {\n  list-style: none;\n  padding-left: 0;\n}\n\n.pif-container .table-of-contents li {\n  padding: 8px 0;\n  border-bottom: 1px solid #e2e8f0;\n}\n\n.pif-container .table-of-contents li:last-child {\n  border-bottom: none;\n}\n\n.pif-container .table-of-contents a {\n  color: #4a5568;\n  text-decoration: none;\n  font-size: 14px;\n  transition: color .3s ease;\n  display: block;\n  padding: 4px 8px;\n  border-radius: 4px;\n}\n\n.pif-container .table-of-contents a:hover {\n  color: #b8860b;\n  background: rgba(184,134,11,.1);\n}\n\n.pif-container .protocol-cards {\n  display: grid;\n  grid-template-columns: repeat(3,1fr);\n  gap: 24px;\n  margin: 32px 0;\n}\n\n.pif-container .protocol-card {\n  background: #fff;\n  border: 2px solid #e2e8f0;\n  border-radius: 12px;\n  padding: 0;\n  box-shadow: 0 4px 12px rgba(0,0,0,.08);\n  transition: all .3s ease;\n  overflow: hidden;\n}\n\n.pif-container .protocol-card:hover {\n  border-color: #b8860b;\n  box-shadow: 0 8px 20px rgba(184,134,11,.15);\n  transform: translateY(-2px);\n}\n\n.pif-container .card-header {\n  background: linear-gradient(135deg,#b8860b 0%,#a0750a 100%);\n  color: #fff;\n  padding: 20px;\n  text-align: center;\n}\n\n.pif-container .card-header h3 {\n  margin: 0 0 12px 0;\n  font-size: 1.1rem;\n  font-weight: 600;\n}\n\n.pif-container .dosage-highlight {\n  background: rgba(255,255,255,.2);\n  color: #fff;\n  padding: 8px 16px;\n  border-radius: 20px;\n  font-size: 1.2rem;\n  font-weight: 700;\n  display: inline-block;\n}\n\n.pif-container .card-content {\n  padding: 24px;\n}\n\n.pif-container .protocol-detail {\n  display: flex;\n  justify-content: space-between;\n  align-items: center;\n  padding: 12px 0;\n  border-bottom: 1px solid #f1f1f1;\n}\n\n.pif-container .protocol-detail:last-child {\n  border-bottom: none;\n}\n\n.pif-container .protocol-detail .label {\n  font-weight: 600;\n  color: #4a5568;\n  font-size: .9rem;\n}\n\n.pif-container .protocol-detail .value {\n  color: #2d3748;\n  font-weight: 500;\n  text-align: right;\n}\n\n.pif-container .pros-cons {\n  display: grid;\n  grid-template-columns: 1fr 1fr;\n  gap: 24px;\n  margin: 32px 0;\n}\n\n.pif-container .pros {\n  background: #f0fff4;\n  padding: 24px;\n  border-radius: 8px;\n  border: 1px solid #c6f6d5;\n  border-left: 4px solid #48bb78;\n}\n\n.pif-container .cons {\n  background: #fffafa;\n  padding: 24px;\n  border-radius: 8px;\n  border: 1px solid #fed7d7;\n  border-left: 4px solid #fc8181;\n}\n\n.pif-container .pros h3 {\n  color: #38a169;\n  margin-bottom: 12px;\n  font-weight: 500;\n}\n\n.pif-container .cons h3 {\n  color: #e53e3e;\n  margin-bottom: 12px;\n  font-weight: 500;\n}\n\n.pif-container .pros ul,\n.pif-container .cons ul {\n  margin: 10px 0;\n  padding-left: 28px;\n  line-height: 1.8;\n}\n\n.pif-container .disclaimer {\n  background: #dc2626;\n  color: #fff;\n  padding: 40px;\n  border-radius: 8px;\n  margin: 60px 0;\n  box-shadow: 0 4px 20px rgba(220,38,38,.2);\n}\n\n.pif-container .disclaimer h3 {\n  margin-bottom: 16px;\n  font-weight: 600;\n}\n\n@media (max-width: 768px) {\n  .pif-container {\n    padding: 30px 24px;\n  }\n\n  .pif-container .container {\n    padding: 0;\n  }\n\n  .pif-container .blog-header {\n    padding: 45px 22px;\n    margin-bottom: 50px;\n    box-shadow: none;\n    border: none;\n    border-left: 4px solid #b8860b;\n    background: #fff;\n  }\n\n  .pif-container .blog-title {\n    font-size: clamp(1.6rem, 5vw, 1.85rem);\n    margin-bottom: 22px;\n    line-height: 1.35;\n  }\n\n  .pif-container .blog-meta {\n    flex-direction: column;\n    gap: 10px;\n    margin-bottom: 26px;\n    font-size: clamp(0.95rem, 2.5vw, 1rem);\n  }\n\n  .pif-container .blog-summary {\n    padding: 22px 18px;\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    border: none;\n    border-left: 4px solid #b8860b;\n    background: rgba(184,134,11,0.05);\n  }\n\n  .pif-container .medical-alert {\n    padding: 22px 18px;\n    margin-bottom: 50px;\n    box-shadow: none;\n    border: none;\n    border-left: 4px solid #dc2626;\n    background: #fff;\n  }\n\n  .pif-container .medical-alert::before {\n    display: none;\n  }\n\n  .pif-container .medical-alert h2 {\n    font-size: clamp(1.15rem, 3vw, 1.25rem);\n    margin-bottom: 20px;\n  }\n\n  .pif-container .medical-alert p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    margin: 14px 0;\n  }\n\n  .pif-container .medical-alert ul {\n    margin: 16px 0;\n    padding-left: 28px;\n    line-height: 1.8;\n  }\n\n  .pif-container .medical-alert ul li {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    margin-bottom: 10px;\n  }\n\n  .pif-container .treatment-comparison {\n    padding: 22px 18px;\n    margin: 40px 0;\n    box-shadow: none;\n    border: none;\n    border-left: 4px solid #48bb78;\n    background: #fff;\n  }\n\n  .pif-container .treatment-comparison h3 {\n    font-size: clamp(1.05rem, 2.8vw, 1.15rem);\n    margin-bottom: 16px;\n  }\n\n  .pif-container .treatment-comparison p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    margin: 14px 0;\n  }\n\n  .pif-container .treatment-comparison ul {\n    margin: 18px 0;\n    padding-left: 28px;\n    line-height: 1.8;\n  }\n\n  .pif-container .treatment-comparison ul li {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    margin-bottom: 10px;\n  }\n\n  .pif-container .table-of-contents {\n    padding: 22px 18px;\n    margin: 50px 0;\n    box-shadow: none;\n    border: none;\n    border-left: 4px solid #b8860b;\n    background: #fff;\n  }\n\n  .pif-container .table-of-contents h3 {\n    font-size: clamp(1.1rem, 3vw, 1.2rem);\n    margin-bottom: 20px;\n  }\n\n  .pif-container .table-of-contents a {\n    font-size: clamp(0.95rem, 1.2vw, 1rem);\n    padding: 8px 12px;\n    line-height: 1.65;\n  }\n\n  .pif-container .section {\n    padding: 22px 18px;\n    margin-bottom: 60px;\n    box-shadow: none;\n    border: none;\n    border-left: 4px solid #b8860b;\n    background: #fff;\n  }\n\n  .pif-container .section-title {\n    font-size: clamp(1.25rem, 3.5vw, 1.4rem);\n    padding-bottom: 20px;\n    margin-bottom: 32px;\n  }\n\n  .pif-container .subsection {\n    margin-bottom: 35px;\n  }\n\n  .pif-container .subsection h3 {\n    font-size: clamp(1.08rem, 2.8vw, 1.15rem);\n    margin-bottom: 18px;\n  }\n\n  .pif-container .subsection p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    margin: 14px 0;\n  }\n\n  .pif-container .subsection ul {\n    margin: 16px 0;\n    padding-left: 28px;\n    line-height: 1.8;\n  }\n\n  .pif-container .subsection ul li {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    margin-bottom: 10px;\n  }\n\n  .pif-container .definition-box,\n  .pif-container .critical-box,\n  .pif-container .regulatory-warning,\n  .pif-container .evidence-box {\n    padding: 22px 18px;\n    margin: 40px 0;\n    box-shadow: none;\n    border-top: none;\n    border-right: none;\n    border-bottom: none;\n    background: #fff;\n  }\n\n  .pif-container .definition-box h3,\n  .pif-container .critical-box h3,\n  .pif-container .regulatory-warning h3,\n  .pif-container .evidence-box h3 {\n    font-size: clamp(1.05rem, 2.8vw, 1.15rem);\n    margin-bottom: 16px;\n  }\n\n  .pif-container .definition-box p,\n  .pif-container .critical-box p,\n  .pif-container .regulatory-warning p,\n  .pif-container .evidence-box p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    margin: 14px 0;\n  }\n\n  .pif-container .definition-box ul,\n  .pif-container .evidence-box ul {\n    margin: 16px 0;\n    padding-left: 28px;\n    line-height: 1.8;\n  }\n\n  .pif-container .definition-box ul li,\n  .pif-container .evidence-box ul li {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    margin-bottom: 10px;\n  }\n\n  .pif-container .pros-cons {\n    grid-template-columns: 1fr;\n    gap: 24px;\n    margin: 40px 0;\n  }\n\n  .pif-container .pros,\n  .pif-container .cons {\n    padding: 22px 18px;\n    box-shadow: none;\n    border-top: none;\n    border-right: none;\n    border-bottom: none;\n    background: #fff;\n  }\n\n  .pif-container .pros h3,\n  .pif-container .cons h3 {\n    font-size: clamp(1.05rem, 2.8vw, 1.15rem);\n    margin-bottom: 16px;\n  }\n\n  .pif-container .pros ul,\n  .pif-container .cons ul {\n    margin: 14px 0;\n    padding-left: 28px;\n    line-height: 1.8;\n  }\n\n  .pif-container .pros ul li,\n  .pif-container .cons ul li {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    margin-bottom: 10px;\n  }\n\n  .pif-container .protocol-cards {\n    grid-template-columns: 1fr;\n    gap: 24px;\n    margin: 40px 0;\n  }\n\n  .pif-container .disclaimer {\n    padding: 22px 18px;\n    margin: 50px 0;\n  }\n\n  .pif-container .disclaimer h3 {\n    font-size: clamp(1.1rem, 3vw, 1.2rem);\n    margin-bottom: 16px;\n  }\n\n  .pif-container .disclaimer p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem);\n    line-height: 1.8;\n    margin: 12px 0;\n  }\n\n  .pif-container article > div[style*=\"background:#fff\"] {\n    padding: 22px 18px !important;\n    margin-top: 50px !important;\n    box-shadow: none !important;\n    border: none !important;\n    border-left: 4px solid #b8860b !important;\n  }\n\n  .pif-container article > div[style*=\"background:#fff\"] h3 {\n    font-size: clamp(1.2rem, 3.5vw, 1.35rem) !important;\n    margin-bottom: 20px !important;\n  }\n\n  .pif-container article > div[style*=\"background:#fff\"] p {\n    font-size: clamp(0.95rem, 1.2vw, 1.05rem) !important;\n    line-height: 1.8 !important;\n    margin: 16px 0 !important;\n  }\n\n  .pif-container article > footer {\n    padding: 22px 18px !important;\n    margin-top: 50px !important;\n  }\n\n  .pif-container article > footer p {\n    font-size: clamp(0.9rem, 2.3vw, 0.95rem) !important;\n    line-height: 1.8 !important;\n    margin: 10px 0 !important;\n  }\n}\n\n@media (max-width: 480px) {\n  .pif-container {\n    padding: 25px 20px;\n  }\n\n  .pif-container .blog-header {\n    padding: 40px 18px;\n  }\n\n  .pif-container .section {\n    padding: 22px 18px;\n  }\n\n  .pif-container .definition-box,\n  .pif-container .treatment-comparison,\n  .pif-container .critical-box,\n  .pif-container .regulatory-warning,\n  .pif-container .evidence-box,\n  .pif-container .pros,\n  .pif-container .cons {\n    padding: 22px 18px;\n  }\n\n  .pif-container .medical-alert,\n  .pif-container .table-of-contents,\n  .pif-container .disclaimer {\n    padding: 22px 18px;\n  }\n}\n<\/style>\n\n<div class=\"pif-container\">\n  <div class=\"container\">\n    <article class=\"blog-post\">\n      <header class=\"blog-header\">\n        <h1 class=\"blog-title\">Tratamientos PIF: GS-441524, Remdesivir y LANZI<\/h1>\n        <div class=\"blog-meta\">\n          <span>\ud83d\udcc5 Actualizado 2026<\/span>\n          <span>\ud83e\ude7a Basado en Evidencia<\/span>\n          <span>\u23f1\ufe0f 20 min de lectura<\/span>\n          <span>\ud83d\udc31 Informaci\u00f3n Veterinaria<\/span>\n        <\/div>\n        <div class=\"blog-summary\">\n          <strong>Gu\u00eda completa:<\/strong> La Peritonitis Infecciosa Felina ya no es una sentencia de muerte. Repasamos los principales tratamientos antivirales disponibles: GS-441524, Remdesivir y la formulaci\u00f3n comercial LANZI.\n        <\/div>\n      <\/header>\n\n      <div class=\"main-content\">\n        <div class=\"medical-alert\">\n          <h2>Aviso M\u00e9dico Cr\u00edtico<\/h2>\n          <p>Estos tratamientos deben realizarse siempre bajo supervisi\u00f3n veterinaria.<\/p>\n          <ul>\n            <li><strong>Supervisi\u00f3n profesional:<\/strong> Todos estos tratamientos requieren seguimiento veterinario<\/li>\n            <li><strong>Consentimiento informado:<\/strong> El tutor debe conocer coste total, tasa de \u00e9xito y posibles reca\u00eddas<\/li>\n            <li><strong>Seguimiento cl\u00ednico:<\/strong> Anal\u00edtica completa con bioqu\u00edmica cada 2-4 semanas para dar seguimiento a su curaci\u00f3n y ajustar dosis si procede. Un gato en tratamiento parece sano exteriormente a las 3 semanas.<\/li>\n          <\/ul>\n          <p style=\"background:#fff; padding:15px; border-radius:10px; margin-top:15px; color:#92400e;\">\n            <strong>Esperanza:<\/strong> Hoy existen antivirales efectivos que logran la remisi\u00f3n en la mayor\u00eda de los gatos tratados cuando se diagnostican a tiempo.\n          <\/p>\n        <\/div>\n\n        <div class=\"treatment-comparison\">\n          <h3>Revoluci\u00f3n en el tratamiento PIF<\/h3>\n          <p>La Peritonitis Infecciosa Felina era 100% mortal hasta hace pocos a\u00f1os (2019). Hoy, gracias a los antivirales de \u00faltima generaci\u00f3n, <strong>la mayor\u00eda de los gatos diagnosticados a tiempo pueden sobrevivir y llevar una vida normal.<\/strong><\/p>\n        <\/div>\n\n        <div class=\"table-of-contents\">\n          <h3>\u00cdndice de contenidos<\/h3>\n          <nav role=\"navigation\" aria-label=\"\u00cdndice de contenidos\">\n            <ul>\n              <li><a href=\"#gs441524\">1. GS-441524: El antiviral de referencia<\/a><\/li>\n              <li><a href=\"#remdesivir\">2. Remdesivir: Alternativa hospitalaria<\/a><\/li>\n              <li><a href=\"#formulaciones-comerciales\">3. Formulaciones comerciales de GS-441524<\/a><\/li>\n              <li><a href=\"#lanzi\">LANZI<\/a><\/li>\n              <li><a href=\"#consideraciones-legales\">4. Requisitos pr\u00e1cticos del tratamiento con LANZI<\/a><\/li>\n              <li><a href=\"#conclusion\">5. Conclusi\u00f3n<\/a><\/li>\n            <\/ul>\n          <\/nav>\n        <\/div>\n\n        <section class=\"section\" id=\"gs441524\">\n          <h2 class=\"section-title\">1. GS-441524: El antiviral de referencia<\/h2>\n\n          <div class=\"subsection\">\n            <h3>Qu\u00e9 es<\/h3>\n            <div class=\"definition-box\">\n              <h3>Mecanismo de acci\u00f3n<\/h3>\n              <p>GS-441524 es un <strong>an\u00e1logo de adenosina<\/strong> (familia de nucle\u00f3sidos) que bloquea la ARN polimerasa del FCoV mutado, el virus causante de la PIF.<\/p>\n              <p style=\"margin-top:15px;\">Act\u00faa interrumpiendo la replicaci\u00f3n viral. Al integrarse en el ARN del virus, provoca la terminaci\u00f3n prematura de la cadena y evita que el virus se multiplique. Tiene una vida media en el organismo de aproximadamente 24 horas (seg\u00fan estudios de Pedersen et al., 2019).<\/p>\n            <\/div>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Evidencia cient\u00edfica<\/h3>\n            <div class=\"evidence-box\">\n              <h3>Estudios documentados<\/h3>\n              <ul>\n                <li><strong><a href=\"https:\/\/ccah.vetmed.ucdavis.edu\/sites\/g\/files\/dgvnsk4586\/files\/inline-files\/Summary%20of%20GS-441524%20treatment%20v5.pdf\" target=\"_blank\" rel=\"noopener\">Primer estudio de campo en 2019<\/a><\/strong> (Pedersen, UC Davis) report\u00f3 tasa de remisi\u00f3n del <strong>80% en gatos tratados durante 84 d\u00edas<\/strong><\/li>\n                <li><strong><a href=\"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/717\" target=\"_blank\" rel=\"noopener\">Revisiones de 2023-2025<\/a><\/strong> con m\u00e1s de 650 gatos muestran <strong>84-85% de supervivencia<\/strong> incluyendo casos con reca\u00eddas tratadas<\/li>\n                <li><strong>En casos neurol\u00f3gicos y oculares<\/strong>, se requieren dosis m\u00e1s altas y el tratamiento dura los mismos 84 d\u00edas.<\/li>\n              <\/ul>\n            <\/div>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Protocolos de dosificaci\u00f3n (GS-441524 con LANZI)<\/h3>\n            <p><strong>Dosis por presentaci\u00f3n cl\u00ednica (cada 24 horas, v\u00eda inyectada (subcut\u00e1nea) salvo indicaci\u00f3n cl\u00ednica distinta):<\/strong><\/p>\n            <p>La v\u00eda oral requiere duplicar la dosis para obtener el mismo efecto. Al inicio del tratamiento lo habitual es la v\u00eda inyectada.<\/p>\n            <ul>\n              <li>H\u00famedo abdominal: 6 mg\/kg<\/li>\n              <li>H\u00famedo pleural: 7 mg\/kg<\/li>\n              <li>Seco: 8 mg\/kg<\/li>\n              <li>Ocular: 8 mg\/kg<\/li>\n              <li>Neuro: 10 mg\/kg<\/li>\n            <\/ul>\n            <p><strong>Duraci\u00f3n:<\/strong><\/p>\n            <ul>\n              <li>84 d\u00edas, sujeto a evoluci\u00f3n favorable<\/li>\n            <\/ul>\n            <p><strong>Ajustes y casu\u00edsticas:<\/strong><\/p>\n            <ul>\n              <li>Anemia marcada: aumentar +2 mg\/kg sobre la dosis indicada<\/li>\n              <li>Hipotermia: m\u00ednimo 10 mg\/kg cada 12 h hasta estabilizaci\u00f3n; despu\u00e9s ajustar progresivamente hasta 15 mg\/kg cada 24 h<\/li>\n              <li>Corticoides: solo en casos oculares, neurol\u00f3gicos y cuando hay hipotermia<\/li>\n            <\/ul>\n            <p><strong>Respuesta cl\u00ednica esperada:<\/strong><\/p>\n            <ul>\n              <li>Fiebre: debe remitir en \u226448 h<\/li>\n              <li>Apetito y actividad: mejora en \u22645 d\u00edas<\/li>\n              <li>Si no mejora seg\u00fan lo anterior, incrementar la dosis de inmediato<\/li>\n            <\/ul>\n          <\/div>\n\n          <div class=\"pros-cons\">\n            <div class=\"pros\">\n              <h3>Ventajas<\/h3>\n              <ul>\n                <li>Alta tasa de \u00e9xito si se inicia pronto<\/li>\n                <li>Amplia experiencia cl\u00ednica publicada<\/li>\n                <li>Es posible la administraci\u00f3n oral domiciliaria, facilitando mucho el tratamiento.<\/li>\n              <\/ul>\n            <\/div>\n            <div class=\"cons\">\n              <h3>Limitaciones<\/h3>\n              <ul>\n                <li>La administraci\u00f3n inyectable puede requerir ayuda experta (veterinarios o ATVs).<\/li>\n                <li>Es imprescindible tratar a la misma hora durante 84 d\u00edas de forma ininterrumpida.<\/li>\n                <li>Existe una tasa de reca\u00eddas que requiere un segundo tratamiento siempre a mayor dosis.<\/li>\n              <\/ul>\n            <\/div>\n          <\/div>\n        <\/section>\n\n        <section class=\"section\" id=\"remdesivir\">\n          <h2 class=\"section-title\">2. Remdesivir: Alternativa hospitalaria<\/h2>\n\n          <div class=\"subsection\">\n            <h3>Qu\u00e9 es<\/h3>\n            <div class=\"definition-box\">\n              <h3>Prof\u00e1rmaco<\/h3>\n              <p>Remdesivir es un <strong>prof\u00e1rmaco que se metaboliza a GS-441524 en el organismo.<\/strong><\/p>\n            <\/div>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Uso en PIF<\/h3>\n            <div class=\"treatment-comparison\">\n              <h3>Indicaciones espec\u00edficas<\/h3>\n              <p>En los pa\u00edses donde est\u00e1 accesible, suele administrarse en los primeros d\u00edas y luego se hace transici\u00f3n a GS-441524 oral para completar el protocolo.<\/p>\n            <\/div>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Protocolos actuales<\/h3>\n            <p><strong>Dosis<\/strong><\/p>\n            <ul>\n              <li>Para lograr una exposici\u00f3n equivalente, la dosis de Remdesivir es aproximadamente el doble que la de GS-441524.<\/li>\n            <\/ul>\n            <p><strong>Uso cl\u00ednico (Protocolo IFSM)<\/strong><\/p>\n            <ul>\n              <li>Inicio intravenoso en cl\u00ednica y continuaci\u00f3n con GS-441524 oral hasta completar 84 d\u00edas, seg\u00fan evoluci\u00f3n.<\/li>\n            <\/ul>\n            <p><strong>Disponibilidad en Espa\u00f1a<\/strong><\/p>\n            <ul>\n              <li>No disponible para pr\u00e1ctica veterinaria habitual.<\/li>\n            <\/ul>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Evidencia<\/h3>\n            <div class=\"evidence-box\">\n              <h3>Resultados documentados<\/h3>\n              <p><a href=\"https:\/\/icatcare.org\/resources\/icatcare_fipupdate_july25.pdf\" target=\"_blank\" rel=\"noopener\">Estudios de 2023-2024 en Reino Unido y Australia<\/a> muestran <strong>tasas de supervivencia comparables a GS-441524<\/strong> cuando se combina con terapia oral de continuaci\u00f3n.<\/p>\n            <\/div>\n          <\/div>\n        <\/section>\n\n        <section class=\"section\" id=\"formulaciones-comerciales\">\n          <h2 class=\"section-title\">3. Formulaciones comerciales de GS-441524<\/h2>\n\n          <div class=\"regulatory-warning\">\n            <h3>Importante sobre formulaciones comerciales<\/h3>\n            <p>En el mercado existen varias marcas no licenciadas que contienen GS-441524. Existen centenares de marcas en el mercado, pero LANZI destaca por su pureza, estabilidad y eficacia cl\u00ednica.<\/p>\n            <p style=\"margin-top:15px;\"><strong>\u26a0\ufe0f Importante:<\/strong>  no todos los productos ofrecen la misma calidad. Por eso, es clave  contar con el criterio de un veterinario que supervise y adapte el tratamiento en cada caso.<\/p>\n          <\/div>\n\n          <div class=\"subsection\" id=\"lanzi\">\n            <h3>LANZI<\/h3>\n            <div class=\"definition-box\">\n              <h3>Caracter\u00edsticas distintivas<\/h3>\n              <ul>\n                <li>Formulaci\u00f3n comercial muy valorada por su pureza y estabilidad<\/li>\n                <li>Destaca por su buena biodisponibilidad oral y facilidad de dosificaci\u00f3n<\/li>\n                <li>Ventaja log\u00edstica por la rapidez en su disponibilidad.<\/li>\n                <li>Disponible en formulaci\u00f3n oral en peque\u00f1as pastillas f\u00e1ciles de administrar y tambi\u00e9n en inyectable.<\/li>\n              <\/ul>\n            <\/div>\n          <\/div>\n        <\/section>\n\n        <section class=\"section\" id=\"consideraciones-legales\">\n          <h2 class=\"section-title\">4. Requisitos pr\u00e1cticos del tratamiento con LANZI<\/h2>\n\n          <ul>\n            <li>Tratar durante 84 d\u00edas siempre a la misma hora y de forma ininterrumpida. La hora se puede adelantar; para atrasar, aplicar una dosis intermedia.<\/li>\n            <li>Recalcular semanalmente la dosis (mg\/kg) porque el gato suele ganar peso, algo que siempre debe suceder en gatos j\u00f3venes.<\/li>\n          <\/ul>\n          <br>\n          <div class=\"subsection\">\n            <h3>Seguimiento cl\u00ednico<\/h3>\n            <p>Anal\u00edtica completa con bioqu\u00edmica cada 2-4 semanas para dar seguimiento a su curaci\u00f3n y ajustar dosis si procede. Un gato en tratamiento parece sano exteriormente a las 3 semanas.<\/p>\n          <\/div>\n\n          <div class=\"subsection\">\n            <h3>Antes de finalizar<\/h3>\n            <p>Antes del d\u00eda 84 y siempre antes de parar, realizar anal\u00edtica completa y confirmar cl\u00ednicamente que procede finalizar. No detener sin pruebas.<\/p>\n          <\/div>\n        <\/section>\n\n        <section class=\"section\" id=\"conclusion\">\n          <h2 class=\"section-title\">5. Conclusi\u00f3n<\/h2>\n\n          <div class=\"treatment-comparison\">\n            <h3>Estado actual del tratamiento PIF<\/h3>\n            <p><strong>La PIF ya no es una sentencia de muerte.<\/strong> Hoy existen antivirales efectivos que logran la remisi\u00f3n en la mayor\u00eda de los gatos tratados.<\/p>\n            \n            <ul>\n              <li><strong>GS-441524<\/strong> sigue siendo la primera l\u00ednea<\/li>\n              <li><strong>Remdesivir<\/strong> puede emplearse al inicio por v\u00eda IV seg\u00fan protocolo IFSM, con continuaci\u00f3n en GS-441524 oral hasta completar 84 d\u00edas; en Espa\u00f1a no est\u00e1 disponible para pr\u00e1ctica veterinaria habitual.<\/li>\n              <li><strong>LANZI<\/strong> es la opci\u00f3n comercial recomendada, siempre bajo supervisi\u00f3n profesional<\/li>\n            <\/ul>\n          <\/div>\n\n          <div class=\"definition-box\">\n            <h3>\ud83d\udca1 Recomendaci\u00f3n<\/h3>\n            <p>Consulta siempre con un veterinario especializado en medicina felina para dise\u00f1ar un protocolo de tratamiento seguro, eficaz y adaptado al estado de tu gato.<\/p>\n          <\/div>\n        <\/section>\n\n        <div class=\"disclaimer\">\n          <h3>\u26a0\ufe0f Disclaimer M\u00e9dico<\/h3>\n          <p><strong>Esta informaci\u00f3n es exclusivamente educativa y no sustituye la consulta veterinaria profesional. Todos los tratamientos deben realizarse bajo prescripci\u00f3n y seguimiento de un veterinario.<\/strong><\/p>\n        <\/div>\n      <\/div>\n\n      <div style=\"background:#fff;border-radius:8px;padding:50px;margin-top:60px;text-align:center;border:1px solid #e2e8f0;box-shadow:0 2px 10px rgba(0,0,0,.05);\">\n        <h3 style=\"color:#2d3748;margin-bottom:24px;font-weight:600;font-size:1.3rem;\">\u00bfTu gato necesita tratamiento para PIF?<\/h3>\n        <p style=\"margin:24px 0;font-size:1.05rem;color:#4a5568;line-height:1.6;\">La PIF ya no es mortal. Con los tratamientos actuales, la mayor\u00eda de gatos diagnosticados a tiempo pueden curarse.<\/p>\n        <p style=\"margin:20px 0;font-size:1rem;color:#b8860b;font-weight:500;\">\"Hoy existen antivirales efectivos que logran la remisi\u00f3n en la mayor\u00eda de los gatos tratados\"<\/p>\n      <\/div>\n\n      <footer style=\"background:#f8f9fa;padding:25px;border-radius:15px;margin-top:40px;text-align:center;font-size:14px;color:#666;border:1px solid #e9ecef;\">\n        <p><strong>Tratamientos PIF: Gu\u00eda Completa 2026<\/strong> \u2014 Informaci\u00f3n veterinaria especializada<\/p>\n        <p style=\"margin:10px 0;\">\u2705 Basada en evidencia cient\u00edfica | \u2705 Informaci\u00f3n actualizada 2026 | \u2705 Solo uso veterinario<\/p>\n        <p style=\"margin-top:15px;font-size:12px;opacity:.8;\">Actualizaci\u00f3n: Marzo 2026 | Consulte siempre con un profesional veterinario<\/p>\n      <\/footer>\n    <\/article>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.pif-container .table-of-contents a').forEach(function(link) {\n    link.addEventListener('click', function(e) {\n      e.preventDefault();\n      var target = document.querySelector(link.getAttribute('href'));\n      if (target) {\n        target.scrollIntoView({ behavior: 'smooth' });\n      }\n    });\n  });\n})();\n<\/script><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row height_medium\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>La PIF ya no es una sentencia de muerte. Descubre c\u00f3mo antivirales como GS-441524, Remdesivir y LANZI est\u00e1n cambiando la vida de miles de gatos.<\/p>\n","protected":false},"author":1,"featured_media":7849,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41],"tags":[],"class_list":["post-7842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tratamientos-pif"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GS-441524 para PIF en Gatos: Resultados y Dosis (2026)<\/title>\n<meta name=\"description\" content=\"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GS-441524 para PIF en Gatos: Resultados y Dosis (2026)\" \/>\n<meta property=\"og:description\" content=\"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/\" \/>\n<meta property=\"og:site_name\" content=\"Lanzi\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T06:06:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T12:13:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/#\\\/schema\\\/person\\\/4fe0d7a49e182804f9297e7928409102\"},\"headline\":\"Tratamientos PIF: GS-441524, Remdesivir y LANZI\",\"datePublished\":\"2025-10-13T06:06:16+00:00\",\"dateModified\":\"2026-04-07T12:13:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/\"},\"wordCount\":4431,\"image\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lanzifip.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Tratamientos-PIF-scaled.jpg\",\"articleSection\":[\"Tratamientos PIF\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/\",\"url\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/\",\"name\":\"GS-441524 para PIF en Gatos: Resultados y Dosis (2026)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lanzifip.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Tratamientos-PIF-scaled.jpg\",\"datePublished\":\"2025-10-13T06:06:16+00:00\",\"dateModified\":\"2026-04-07T12:13:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/#\\\/schema\\\/person\\\/4fe0d7a49e182804f9297e7928409102\"},\"description\":\"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lanzifip.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Tratamientos-PIF-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/lanzifip.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Tratamientos-PIF-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"Tratamientos PIF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tratamientos PIF: GS-441524, Remdesivir y LANZI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/\",\"name\":\"Lanzi FIP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/#\\\/schema\\\/person\\\/4fe0d7a49e182804f9297e7928409102\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/lanzifip.com\"],\"url\":\"https:\\\/\\\/lanzifip.com\\\/en\\\/author\\\/admin_2r7rwygz\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GS-441524 para PIF en Gatos: Resultados y Dosis (2026)","description":"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/","og_locale":"en_US","og_type":"article","og_title":"GS-441524 para PIF en Gatos: Resultados y Dosis (2026)","og_description":"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.","og_url":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/","og_site_name":"Lanzi","article_published_time":"2025-10-13T06:06:16+00:00","article_modified_time":"2026-04-07T12:13:17+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#article","isPartOf":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/"},"author":{"name":"admin","@id":"https:\/\/lanzifip.com\/en\/#\/schema\/person\/4fe0d7a49e182804f9297e7928409102"},"headline":"Tratamientos PIF: GS-441524, Remdesivir y LANZI","datePublished":"2025-10-13T06:06:16+00:00","dateModified":"2026-04-07T12:13:17+00:00","mainEntityOfPage":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/"},"wordCount":4431,"image":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#primaryimage"},"thumbnailUrl":"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg","articleSection":["Tratamientos PIF"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/","url":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/","name":"GS-441524 para PIF en Gatos: Resultados y Dosis (2026)","isPartOf":{"@id":"https:\/\/lanzifip.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#primaryimage"},"image":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#primaryimage"},"thumbnailUrl":"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg","datePublished":"2025-10-13T06:06:16+00:00","dateModified":"2026-04-07T12:13:17+00:00","author":{"@id":"https:\/\/lanzifip.com\/en\/#\/schema\/person\/4fe0d7a49e182804f9297e7928409102"},"description":"Descubre los tratamientos m\u00e1s efectivos para la PIF felina: GS-441524, Remdesivir y LANZI. Evidencia cl\u00ednica, dosis y protocolos actualizados.","breadcrumb":{"@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#primaryimage","url":"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg","contentUrl":"https:\/\/lanzifip.com\/wp-content\/uploads\/2025\/10\/Tratamientos-PIF-scaled.jpg","width":2560,"height":1707,"caption":"Tratamientos PIF"},{"@type":"BreadcrumbList","@id":"https:\/\/lanzifip.com\/en\/tratamientos-pif-gs-441524-remdesivir-y-lanzi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lanzifip.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tratamientos PIF: GS-441524, Remdesivir y LANZI"}]},{"@type":"WebSite","@id":"https:\/\/lanzifip.com\/en\/#website","url":"https:\/\/lanzifip.com\/en\/","name":"Lanzi FIP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lanzifip.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lanzifip.com\/en\/#\/schema\/person\/4fe0d7a49e182804f9297e7928409102","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2d6e44b69c2191c4019854d32ae09061bd5bd2437e70891da339b080e1b1b261?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/lanzifip.com"],"url":"https:\/\/lanzifip.com\/en\/author\/admin_2r7rwygz\/"}]}},"_links":{"self":[{"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/posts\/7842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/comments?post=7842"}],"version-history":[{"count":6,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/posts\/7842\/revisions"}],"predecessor-version":[{"id":10324,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/posts\/7842\/revisions\/10324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/media\/7849"}],"wp:attachment":[{"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/media?parent=7842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/categories?post=7842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lanzifip.com\/en\/wp-json\/wp\/v2\/tags?post=7842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}